Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile KMT2A rearrange FLT3 exon 14 ins FLT3 D835Y
Therapy FHD-286 + Quizartinib
Indication/Tumor Type acute myeloid leukemia
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KMT2A rearrange FLT3 exon 14 ins FLT3 D835Y acute myeloid leukemia sensitive FHD-286 + Quizartinib Preclinical - Cell line xenograft Actionable In a preclinical study, FHD-286 and Vanflyta (quizartinib) synergistically inhibited viability in acute myeloid leukemia cells harboring a KMT2A rearrangement, FLT3-ITD, and FLT3 D835Y in culture, and resulted in increased survival compared to treatment with Vanflyta (quizartinib) alone in a cell line xenograft model (PMID: 40089460). 40089460
PubMed Id Reference Title Details
(40089460) Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Full reference...